Piramal Pharma Limited — Updates, 20-03-2025: Press Release

BrePco Biopharma Limited and Piramal Critical Care have secured Market Authorization for Neoatricon®, a groundbreaking pediatric formulation for dopamine hydrochloride infusion aimed at treating hypotension in neonates, infants, and children. This product represents a significant innovation as it is the first strength solution tailored for pediatric use, minimizing risks of dosing inaccuracies and preparation time in intensive care settings. The PCC division will oversee commercialization across the EU, UK, and Norway, leveraging this opportunity to enhance health outcomes in vulnerable pediatric populations. The move into this new therapeutic area marks a pivotal expansion for Piramal Critical Care, projected to improve both patient safety and care efficiency in emergency situations. Investors should note the positive implications for market positioning and future growth potential associated with this launch.